ROCKVILLE, Md., Dec. 17, 2015 (GLOBE NEWSWIRE) -- The United States Pharmacopeial Convention (USP) announced that Salah D. Kivlighn, Ph.D., has assumed the role of Senior Vice President, Strategic Marketing and Program Operations (SMPO). Dr. Kivlighn reports to USP's Chief Executive Officer, Ronald T. Piervincenzi, and is a member of the organization's executive team.
A new division in the organizational structure, Strategic Marketing and Program Operations will work in direct partnership with USP's Science Division responsible for the technical and scientific development of USP's quality standards. SMPO will focus on understanding customer needs and specifications, monitoring marketing efficiency and effectiveness and further developing USP's brand strategy.
"Being able to better understand the unmet and emerging needs of our key stakeholders will enable USP to strengthen its quality-related programs in chemical medicines, biologics, excipients, dietary supplements, food ingredients and healthcare practice," said Dr. Kivlighn. The SMPO unit for each of these areas will report to Dr. Kivlighn
Most recently, Dr. Kivlighn was Vice President of Marketing at Kite Pharma, a company focused on cell-based immuno-oncology. For eight years, Kivlighn held global leadership positions in product development and marketing at MedImmune, where he was responsible for regulatory filings; clinical and commercial development and chemistry, manufacturing and controls (CMC) related to numerous oncology and autoimmunity products. Dr. Kivlighn also led marketing teams and initiatives at NABI Biopharmaceuticals and Merck & Co., Inc. related to pipelines, launches and planning for vaccine and cardiovascular products.
Dr. Kivlighn received a B.S. in Distributed Studies from Iowa State University and a Ph.D. in Pharmacology from the University of Houston. Dr. Kivlighn also completed a fellowship in integrated physiology in the Department of Physiology at the University of Mississippi Medical School. He has authored more than 70 peer-reviewed publications and has completed a variety of executive training programs at the Wharton School of Business.
"Being able to leverage the kind of expertise and experience Salah brings with him to USP will help optimize the public health impact of each of our program units," said Dr. Piervincenzi. "We're pleased to have Salah as part of the USP leadership team."
For additional information, contact [email protected].
USP – Global Expertise, Trusted Standards, Improved Health
The U.S. Pharmacopeial Convention (USP) is a global health organization that improves lives through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods. USP's standards are used worldwide. For more information about USP, visit http://www.usp.org.
CONTACT: Theresa Laranang-Mutlu
301-816-8167
[email protected]


United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Robinhood Expands Sports Event Contracts With Player Performance Wagers
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 



